Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment

Metabolism: Clinical and Experimental

Volumn 62, Issue 11, 2013, Pages 1587-1596

  Ciaraldi, Theodore P ^a,b   Aroda, Vanita ^a,b,c   Mudaliar, Sunder R ^a,b   Henry, Robert R ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

Inflammation; Insulin resistance; Thiazolidinediones

Indexed keywords

ADIPONECTIN; CHEMOKINE; CYTOKINE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; GLUCOSE CLAMP TECHNIQUE; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; INFLAMMATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANALYSIS OF COVARIANCE; ANCOVA; BMI; BODY MASS INDEX; C-JUN N-TERMINAL KINASE; COEFFICIENT OF VARIATION; CV; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; DHEA; DHEA-S; FERMAN-GALLOWAY SCORE; FG; GDR; GLUCOSE DISPOSAL RATE; GROΑ; GROWTH-RELATED ONCOGENE ALPHA; HOMA-IR; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; IFNΓ; IGT; IKAPPA B KINASE; IKK; IL; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; INTERFERON GAMMA; INTERLUKIN; JNK; MACROPHAGE INFLAMMATORY PROTEIN-1BETA; MAPK; MCP-1; MIP-1Β; MITOGEN-ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOATTRACTANT PROTEIN-1; NC; NF-KB; NORMAL CYCLING SUBJECT; NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS; PCOS; POLYCYSTIC OVARY SYNDROME; SEX HORMONE BINDING GLOBULIN; SHBG; T; T2D; TESTOSTERONE; THIAZOLIDINEDIONES; TNFΑ; TUMOR NECROSIS FACTOR ALPHA; TYPE 2 DIABETES; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; WAIST-HIP RATIO; WHR;

ADULT; BIOLOGICAL MARKERS; CHEMOKINES; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; METFORMIN; MUSCLE, SKELETAL; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES;

EID: 84886382152     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.07.004     Document Type: Article

References (54)

1. M.F. Gregor, and G.S. Hotamisligil Inflammatiory mechanisms in obesity Annu Rev Immunol 29 2011 415 445
2. J.M. Olefsky, and C.K. Glass Macrophages, inflammation, and insulin resistance Annu Rev Physiol 72 2010 219 246
3. J.-F. Tanti, and J. Jager Cellular mechanisms of insulin resistance: role of stress regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation Curr Opin Pharmacol 9 2009 753 762
4. V. Varma, A. Yao-Borengasser, and N. Rasouli Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action Am J Physiol Endocrinol Metab 296 2009 E1300 E1310
5. L.J. Moran, M.L. Misso, and R.A. Wild Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis Hum Reprod Update 16 2010 347 363
6. Y. Zhao, L. Fu, and R. Li Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomic analysis BMC Med 10 2012
7. J. Vrbikova, and V. Hainer Obesity and the polycystic ovary syndrome Obes Facts 2 2009 26 35
8. P. Moghetti, F. Tosi, and C. Bonin Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome J Clin Endocrinol Metab 98 2013 E628 E637
9. T.P. Ciaraldi, V. Aroda, and S. Mudaliar Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance J Clin Endo Metabol 94 2009 157163
10. M. Mohlig, J. Spranger, and M. Osterhoff The polycystic ovary syndrome per se is not associated with increased chronic inflammation Eur J Endocrinol 150 2004 525 532 (Pubitemid 38584704)
11. V.M. Victor, M. Rocha, and C. Banuls Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance J Clin Endocrinol Metab 96 2011 3115 3122
12. H. Escobar-Morreale, G. Villuendas, and J.I. Botella-Carretero Obesity, not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women Diabetologia 46 2003 625 633 (Pubitemid 36808182)
13. H. Kahal, A. Aburima, and T. Ungivart Polycystic ovary syndrome has no independent effect on vascular, inflammatory or theombotic markers when matched for obesity Clin Endocrinol (Oxf) 79 2012 252 258
14. D. Glintborg, K. Hojlund, and M. Andersen Souluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment Diabetes Care 31 2008 328 334 (Pubitemid 351213346)
15. D. Glintborg, M. Andersen, and B. Richelsen Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1a are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment Clin Endocrinol 71 2009 652 658
16. M. Luque-Ramirez, and H. Escobar-Morreale Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interlukin-6 concentrations Horm Metab Res 42 2010 815 820
17. J. Zawadzki, and A. Dunaif Diagnostic criteria for polycystic ovary syndrome: towards a rational approach J.R. Givens, F. Haseltine, A. Dunaif, Polycystic ovary syndrome 1992 Blackwell Scientific Boston 377 384
18. V. Aroda, T.P. Ciaraldi, and P. Burke Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial J Clin Endo Metabol 94 2009 469 476
19. T.M. Wallace, J.C. Levy, and D.R. Matthews Use and abuse of HOMA modeling Diabetes Care 27 2004 1487 1495 (Pubitemid 38680001)
20. A.W. Thorburn, B. Gumbiner, and F. Bulacan Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin dependent (Type II) diabetes independent of impaired glucose uptake J Clin Invest 85 1990 522 529 (Pubitemid 20070061)
21. T.P. Ciaraldi, L. Abrams, and S. Nikoulina Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects J Clin Invest 96 1995 2820 2827
22. B.S. Schneider, and P.M. Tiidus Neutrophil infiltration in exercise-injured skeletal muscle: how do we resolve the controversy? Sports Med 37 2007 837 856 (Pubitemid 47481626)
23. D.R. Greaves, and S. Gordon Macrophage-specific gene expression: current paradigns and future challenges Int J Hematol 76 2002 6 15 (Pubitemid 43020275)
24. J. Reutershan CXCR2-the receptor to hit? Drug News Perspect 19 2006 615 623
25. B. Kaminska MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits Biochim Biophys Acta 1754 2005 253 262 (Pubitemid 41797706)
26. H. Escobar-Morreale, M. Luque-Ramirez, and F. Gonzalez Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis Fertil Steril 95 2011 1048 1058
27. A.M. Fulghesu, F. Sanna, and S. Uda IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance Mediators Inflamm 2011 2011 8
28. A. Corbould Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type 2 diabetes? Panminerva Med 50 2008 279294
29. S.K. Vijay, M. Mishra, and H. Kumar Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes Acta Diabetol 46 2009 27 33
30. J. Joya-Galeana, M.L. Fernandez, and A. Cervera Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects Diab Metab Res Rev 27 2011 373 382
31. G. Di Gregorio, A. Yao-Borengasser, and N. Rasouli Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone Diabetes 54 2005 2305 2313 (Pubitemid 41134256)
32. H. Shimizu, S. Oh-I, and T. Tsuchiya Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study Diabet Med 23 2006 253 257
33. M. van Doorn, M. Kemme, and M. Ouwens Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers Br J Clin Pharmacol 62 2006 391 402 (Pubitemid 44401522)
34. F. Esfahanian, M.M. Zamani, and R. Heshmat Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome J Obstet Gynaecol Res 39 2013 806 813
35. L. Mohiyiddeen, A.J. Watson, and N.V. Apostolopoulos Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome J Obstet Gynaecol Res 33 2013 165 170
36. J. Jakubowska, A. Bohdanowicz-Pawlak, and A. Milewicz Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment Gynecol Endocrinol 24 2008 378 384 (Pubitemid 352032225)
37. R.S. Legro, R.J. Zaino, and L.M. Demers The effects of metformin and rosiglitazone alone and in combination on the ovary and endometrium in polycystic ovary syndrome Am J Obstet Gynecol 196 2007 1 10
38. M. Mitkov, B. Pehlivanov, and D. Terzieva Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome Eur J Obst Gynecol Repro Biol 126 2006 93 98 (Pubitemid 44294601)
39. Q. Du, Y.J. Wang, and S. Yang A systematic review and meta-analysis of randomoized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome Curr Med Res Opin 28 2012 723 730
40. J.-P. Baillargeon, D.J. Jakubowicz, and M.J. Iuorno Effects of merformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity Fertil Steril 82 2004 893 902 (Pubitemid 39346435)
41. M. Yilmaz, A. Biri, and A. Karakoc The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome J Endocrinol Invest 28 2005 1003 1008 (Pubitemid 43265766)
42. S.M. Sirmans, E. Weidman-Evans, and V. Everton Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications Ann Pharmacother 46 2012 403 418
43. W.Y. Chang, E.S. Knochenhauer, and A.A. Bartolucci Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups Fer. Ster. 83 2005 1717 1723 (Pubitemid 40824804)
44. F. Gonzalez, J. Minium, and N.S. Rote Hyperglycemia alters tumor necrosis factor-alpha release from mononuclear cells in women with polycystic overy syndrome J Clin Endocrinol Metab 90 2005 5336 5342 (Pubitemid 41262298)
45. M.Y. Donath, and S.E. Shoelson Type 2 diabetes as an inflammatory disease Nature Rev Immunol 11 2011 98 107
46. K. Cusi, K. Maezono, and A. Osman Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle J Clin Invest 105 2000 311 320 (Pubitemid 30094451)
47. A.S. Andreasen, M. Kelly, and R.M.G. Berg Type 2 diabetes is associated with altered NF-kB DNA binding activity, JNK phosphorylation, and AMPK phosphorylation in skeletal muscle after LPS PLoS One 6 2011 1 8
48. U.B. Masharani, B.A. Maddux, and X. Li Insulin resistance in non-obese subjects is associated with activation of the JNK pathway and impaired insulin signaling in skeletal muscle PLoS One 6 2011 1 9
49. S. Jackson, S.M. Bagstaff, and S. Lynn Decreased insulin responsiveness of glucose uptake in cultured human skeletal muscle cells from insulin-resistant nondiabetic relatives of type 2 diabetic families Diabetes 49 2000 1169 1177 (Pubitemid 30439092)
50. H.A. Koistinen, A.V. Chilbalin, and J.R. Zierath Aberrant p38 mitogen-activated protein kinase signaling in skeletal muscle from Type 2 diabetic subjects Diabetologia 46 2003 1324 1328 (Pubitemid 37297201)
51. G.K. Bandyopadhyay, J.G. Yu, and J. Ofrecio Increased p85/55/50 expression and decreased phosphatidylinositol 3-kinase activity in insulin-resistant human skeletal muscle Diabetes 54 2005 2351 2359 (Pubitemid 41134262)
52. A. Corbould, H. Zhao, and S. Mirzoeva Enhanced mitogenic signaling in skeletal msucle of women with polycystic ovary syndrome Diabetes 55 2006 751 759 (Pubitemid 43343232)
53. A. Repaci, A. Gambineri, and R. Pasquali The role of low-grade inflammation in the polycystic ovary syndrome Mol Cell Endocrinol 335 2011 30 41
54. M. Luque-Ramirez, J.L. San Milan, and H.F. Escobar-Morreale Genomic variants in polycystic ovary syndrome Clin Chim Acta 366 2006 14 26 (Pubitemid 43330963)